Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275599 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01275599 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 16 participants.
The verdict
NCT01275599, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the drug-drug interaction potential between telaprevir and buprenorphine/naloxone. An understanding of the interaction potential will help to determine whether buprenorphine dose adjustments are necessary for patients who are concomitantly treated with telaprevir. Telaprevir, in combination with other antiviral agents, is being investigated for the treatment of chronic hepatitis C virus infection. Buprenorphine/naloxone is used for maintainance therapy in patients with opioid dependence.
Interventions
- DRUG buprenorphine/naloxone
- DRUG telaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275599
The ClinicalTrials.gov registry entry for NCT01275599 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which buprenorphine/naloxone is the first listed.
NCT01275599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275599 about?
NCT01275599 is a clinical study titled "Drug-Drug Interaction Study Between Telaprevir and Buprenorphine". The purpose of this study is to investigate the drug-drug interaction potential between telaprevir and buprenorphine/naloxone. An understanding of the interaction potential will help to determine whether buprenorphine dose adjustments are necessary for patients who are concomitantly treated with tel...
What is the current status of trial NCT01275599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-01.
What interventions are being tested in trial NCT01275599?
The interventions under investigation include: buprenorphine/naloxone (DRUG), telaprevir (DRUG).
Who is sponsoring clinical trial NCT01275599?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.